Management of patients with resistant or refractory chronic myelogenous leukemia

Alfonso Quintás-Cardama, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML). Despite the outstanding results achieved with imatinib, approximately 20% to 30% of patients may either not respond to therapy or eventually develop resistance or intolerance to the drug. Resistance to imatinib is mediated to a great extent by the emergence of mutations within the tyrosine kinase domain of the BCR-ABL oncogene. A growing number of tyrosine kinase inhibitors (TKIs) with different pharmacokinetic and pharmacodynamic profiles are currently being investigated in clinical trials to determine their efficacy against CML resistant to imatinib therapy. The leading examples of this group of second-generation TKIs are nilotinib (Tasigna) and dasatinib (Sprycel). This review addresses the causes and consequences of imatinib resistance and current management of refractory CML with the second-generation TKIs.

Original languageEnglish (US)
Pages (from-to)430-437
Number of pages8
JournalONCOLOGY
Volume22
Issue number4
StatePublished - Apr 15 2008
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Oncogenes
Imatinib Mesylate
Pharmacokinetics
Clinical Trials
Mutation
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Management of patients with resistant or refractory chronic myelogenous leukemia. / Quintás-Cardama, Alfonso; Cortes, Jorge.

In: ONCOLOGY, Vol. 22, No. 4, 15.04.2008, p. 430-437.

Research output: Contribution to journalReview article

Quintás-Cardama, Alfonso ; Cortes, Jorge. / Management of patients with resistant or refractory chronic myelogenous leukemia. In: ONCOLOGY. 2008 ; Vol. 22, No. 4. pp. 430-437.
@article{349db92e067a43f491426d45055c117d,
title = "Management of patients with resistant or refractory chronic myelogenous leukemia",
abstract = "The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML). Despite the outstanding results achieved with imatinib, approximately 20{\%} to 30{\%} of patients may either not respond to therapy or eventually develop resistance or intolerance to the drug. Resistance to imatinib is mediated to a great extent by the emergence of mutations within the tyrosine kinase domain of the BCR-ABL oncogene. A growing number of tyrosine kinase inhibitors (TKIs) with different pharmacokinetic and pharmacodynamic profiles are currently being investigated in clinical trials to determine their efficacy against CML resistant to imatinib therapy. The leading examples of this group of second-generation TKIs are nilotinib (Tasigna) and dasatinib (Sprycel). This review addresses the causes and consequences of imatinib resistance and current management of refractory CML with the second-generation TKIs.",
author = "Alfonso Quint{\'a}s-Cardama and Jorge Cortes",
year = "2008",
month = "4",
day = "15",
language = "English (US)",
volume = "22",
pages = "430--437",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Management of patients with resistant or refractory chronic myelogenous leukemia

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2008/4/15

Y1 - 2008/4/15

N2 - The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML). Despite the outstanding results achieved with imatinib, approximately 20% to 30% of patients may either not respond to therapy or eventually develop resistance or intolerance to the drug. Resistance to imatinib is mediated to a great extent by the emergence of mutations within the tyrosine kinase domain of the BCR-ABL oncogene. A growing number of tyrosine kinase inhibitors (TKIs) with different pharmacokinetic and pharmacodynamic profiles are currently being investigated in clinical trials to determine their efficacy against CML resistant to imatinib therapy. The leading examples of this group of second-generation TKIs are nilotinib (Tasigna) and dasatinib (Sprycel). This review addresses the causes and consequences of imatinib resistance and current management of refractory CML with the second-generation TKIs.

AB - The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML). Despite the outstanding results achieved with imatinib, approximately 20% to 30% of patients may either not respond to therapy or eventually develop resistance or intolerance to the drug. Resistance to imatinib is mediated to a great extent by the emergence of mutations within the tyrosine kinase domain of the BCR-ABL oncogene. A growing number of tyrosine kinase inhibitors (TKIs) with different pharmacokinetic and pharmacodynamic profiles are currently being investigated in clinical trials to determine their efficacy against CML resistant to imatinib therapy. The leading examples of this group of second-generation TKIs are nilotinib (Tasigna) and dasatinib (Sprycel). This review addresses the causes and consequences of imatinib resistance and current management of refractory CML with the second-generation TKIs.

UR - http://www.scopus.com/inward/record.url?scp=45549088374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549088374&partnerID=8YFLogxK

M3 - Review article

C2 - 18472616

AN - SCOPUS:45549088374

VL - 22

SP - 430

EP - 437

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 4

ER -